However, Frost et al. investigated the efficacy of 1 L pembrolizumab in patients with KRAS-mutated lung adenocarcinoma with high PD-L1 expression (TPS ≥ 50%) and showed a significantly higher ORR and longer PFS in patients harboring KRASG12C/TP53 co-mutations, as compared to patients with KRASnon-G12C/TP53 mutations [28]; these results enhanced the importance of assessing KRAS subtypes and TP53 mutations before pembrolizumab therapy. This evidence concerns the gene CD274 and lung adenocarcinoma.